CLINICAL EVALUATION OF? TISSUE POLYPEPTIDE ANTIGEN & CARCINOEMBRYONIC ANTIGEN IN LUNG CANCER DIAGNOSIS

Abstract

The present study was performed on 70 individuals categorized as follows:

I- Thirty patients suffering from bronchogenic carcinoma, classified according to:

A-Cell type:

• Twenty three cases NSCLC (32.8% of total) (76.66% of bronchogenic carcinoma), 11 of them were adenocarcinoma (15.75 of total) (36.6% of bronchogenic carcinoma) and 12 of them were squamous cell carcinoma (17.14% of total) (40% ofbronchogenic carcinoma).

• Seven cases were SCLC (10% of total) (23.4% ofbronchogenic carcinoma).

B-According to stage:

Twelve of them (17.14% of total) (40% of bronchogenic carcinoma) were stage II, 11 of them (15.71% of total) (36.6% of bronchogenic carcinoma) were stage III and 7 of them 10% of total) (23.4% of bronchogenic carcinotna) were stage IV.

Their ages ranged from 33 to 80 years (means 63) with a mean of 63 years.